Nanotechnology Applications In Medicine

Gold dust injections into the eye may sound like something out of science fiction, but a new study suggests that it could be a groundbreaking approach to treating age-related macular degeneration (AMD) and other retinal conditions. AMD is a leading cause of vision loss worldwide, particularly in older adults, as it damages the macula—the part of the retina responsible for sharp, central vision. While there are treatments available that can slow the progression of AMD, there is currently no cure or way to reverse the damage. Researchers at Brown University, led by biomedical engineer Jiarui Nie, have developed an innovative technique using tiny gold nanoparticles to potentially restore vision lost to retinal degeneration. These gold particles are infused with antibodies that specifically target eye cells and are then injected into the vitreous chamber of the eye. This is the gel-filled area between the retina and lens. Once inside, an infrared laser is used to activate the nanoparticles, which then stimulate the retinal cells in the same way that light-sensitive photoreceptors would. What makes this approach stand out is that it doesn’t require complicated surgeries or genetic modifications. The nanoparticles stay in the retina for several months without causing major toxicity, making it a less invasive treatment option compared to current methods. In the study conducted on mice with retinal disorders, the treatment showed promising results, successfully bypassing the damaged photoreceptors and partially restoring vision. Though the technology has not yet been tested on humans, it represents a significant step toward transforming treatment options for retinal degenerative diseases. Unlike existing treatments for AMD, which often require surgery or large implants, this method is minimally invasive and could potentially be applied using a wearable device, such as glasses with an embedded infrared laser. This new treatment also has the potential to treat related conditions like retinitis pigmentosa. The ability to use nanoparticles to stimulate the visual system could offer a broader field of vision compared to current technologies. While the results in mice are encouraging, further research and refinement will be needed before this technology can be safely approved for human use. As more studies explore how technology can help address eye diseases, such as using retinal cells to replace damaged photoreceptors, this gold nanoparticle approach could mark a significant leap forward in retinal prosthetics. The researchers believe that this method could be key to developing photothermal retinal prostheses, such as wearable goggles, offering hope for future treatments. #Golddust #RMScienceTechInvest

A recent publication in Nature highlights an exciting breakthrough in drug delivery a needle-free insulin system that works through the skin. Researchers developed a smart, depth-responsive polymer that overcomes the long-standing challenge of transdermal insulin delivery by adapting to the skin environment and enabling efficient transport across biological barriers. The results showed effective and sustained blood glucose control in preclinical models without signs of inflammation, pointing toward a future of painless and non-invasive diabetes management. What I find particularly interesting is how this concept of stimuli-responsive polymer systems can be extended beyond insulin delivery. In areas like wound healing and urinary tract infections (UTIs), where biofilms and tissue barriers limit treatment efficacy, such smart delivery platforms could play a transformative role. Designing systems that respond to local environments (like pH or infection signals) to deliver antibiotics, nanoparticles, or even phage therapy could significantly improve targeted treatment outcomes. This kind of interdisciplinary approach combining material science with biomedical applications opens up exciting possibilities for developing next-generation therapeutic strategies. Looking forward to exploring how these concepts can be adapted to tackle real-world clinical challenges. Source: https://lnkd.in/g7JksnSX #Biotechnology #DrugDelivery #Nanomedicine #PhageTherapy #WoundHealing #UTI #Innovation

IL-2. Perfect biology, terrible drug. Regulatory T cells (Tregs) suppress excessive immune responses and prevent autoimmune diseases. IL-2 keeps them alive and proliferating. Activate Tregs and you have the perfect treatment for a whole alphabet soup of diseases: RA, T1D, MS, SLE, IBD. Drug discovery isn’t that simple. The IL-2 receptor exists on other immune cells, the very immune cells that cause the disease. The last thing you want to do is expand those cells. There is a critical difference though. Other cells express β and γ receptor sub-units and have a modest affinity for IL-2. Tregs express an additional α sub-unit, which gives them much higher affinity to IL-2. Treat with IL-2 at low doses and you preferentially activate Tregs. The therapeutic window is brutally narrow though. Researchers have thrown everything at trying to engineer a solution. PEGylation, Fc fusion, IL-2 muteins with modified receptor binding ratios. Marginal improvements but nobody has cracked it. A new paper takes a different approach. Instead of trying to engineer IL-2 they’ve taken an antibody-based approach, developing a trispecific agonist nanobody-Fc fusion that simultaneously engages all three IL-2 receptor sub-units. They analysed affinity and epitope location of nanobodies to the three receptor sub-units. Epitope and geometry mattered far more than affinity. Tighter binding isn’t always the answer, especially when trying to mimic natural receptor assembly. Avidity also helps here. In the final designs they had two copies of the anti-α nanobody to drive binding to cells with higher concentrations of this version of the receptor, i.e. Tregs. Two of the final designs activated Tregs at femtomolar concentrations – more potent than IL-2. Importantly, non-Treg cells only responded at much higher concentration. Seems like a meaningful therapeutic window. As with many of these antibody engineering projects – there’s no way of predicting the best design. You have to build and screen empirically. Don’t tell me AI will figure this out! But it’s not perfect. Tregs suppress inflammation by acting as a sponge for IL-2, starving nearby effector cells by soaking up IL-2. These trispecifics occupy the IL-2 binding site, potentially blunting the passive suppression of Tregs. The authors acknowledge this. The solution is to find nanobodies that work equally well but don’t inhibit IL-2 binding to the receptor. You then maintain passive suppression of IL-2 while preferentially expanding Tregs. Is this finally the answer to the puzzle of targeting IL-2? Still a long way to go before this is proved in the clinic. ---- I’m Ian, I post about protein engineering and the business of biotech. Follow me for great science and questionable humour.

A new 'one-second' spray-on could revolutionize #medicine by instantly stopping #catastrophic #bleeding… #Researchers at the Korea Advanced Institute of Science and Technology (KAIST) have engineered a next-generation '#AGCL powder' that can halt severe bleeding in just one second. Unlike traditional bandages or patches that struggle with irregular or deep gashes, this sprayable solution reacts instantly with ions in the blood to create a robust, #physical #hydrogel barrier. Developed in collaboration with an active-duty #Army Major, the #material is designed specifically for high-pressure situations like combat zones and disaster sites where every second determines whether a patient survives. The powder is made from #biocompatible natural materials including alginate and chitosan, allowing it to absorb seven times its weight in blood while promoting rapid tissue regeneration. Its high #adhesive strength allows it to withstand significant blood pressure, and it remains stable in hot or humid storage for up to two years. Beyond #military use, this 'spin-off' technology is expected to transform #civilian #emergency care and #surgical procedures, offering a reliable, shelf-stable way to prevent blood loss in underserved areas and hospitals alike. source: Son, Y., Pak, K., Lee, T., Prayogo, M. C., Choi, J., Kang, S., Kang, M., Oh, B., Sun, S. Y., Kim, S., Im, S. G., Jon, S., & Park, S. (2025). An Ionic Gelation Powder for Ultrafast Hemostasis and Accelerated Wound Healing. Advanced Functional Materials. #health #healthcare #medicine #education #science #technology

Pig semen cures eye cancer. That is the headline your algorithm wants you to click. Here is what actually happened. Researchers at Shenyang Pharmaceutical University engineered exosomes derived from porcine seminal fluid to carry a nanozyme system across the blood-retina barrier. They loaded these vesicles with carbon dots, manganese dioxide, and glucose oxidase. They conjugated folic acid for selective uptake by retinoblastoma cells. They applied the formulation as eye drops in a mouse model. Tumour growth stopped. Vision was preserved. No injection. No laser. No systemic chemotherapy. The science is elegant. The biology is real. The barrier-crossing properties of seminal exosomes are well documented in reproductive physiology. The team repurposed a natural penetration mechanism for drug delivery across one of the most protected barriers in the body. This is not a gimmick. This is rational bioengineering. But let me add what the headline will not tell you. This is a mouse study. The retinoblastoma model is xenograft-based. The follow-up is 30 days. The sample sizes are small. The translation to paediatric human eyes requires years of safety, formulation, and regulatory work that has barely begun. None of that diminishes the result. It contextualizes it. The real story is not the origin of the exosomes. The real story is that biological vesicles can be engineered to open tight junctions on demand, deliver payloads selectively, and close those junctions again. If that principle holds beyond the retina, the implications extend to the blood-brain barrier, mucosal barriers, and solid tumour microenvironments. One study does not change medicine. But one mechanism, validated across barriers, might. Stop reading headlines. Start reading methods sections.

Scientists found an enzyme that "eats" arterial plaque. The discovery by Italian researchers could eventually replace open-heart surgery. An elite research network across Italy has isolated a specific class of specialized bacterial enzymes capable of naturally breaking down the dense, calcified fatty deposits known as arterial plaque. Published in the European Heart Journal, the preclinical study demonstrates how these highly targeted bio-catalysts can selectively degrade the complex fibrin-lipid matrix that forms the structural foundation of atherosclerosis. Utilizing advanced nanotechnology, scientists engineered biocompatible lipid-shell nanocarriers to encapsulate the enzymes, allowing them to travel through the bloodstream completely undetected by the immune system. Once these smart carriers encounter the precise inflammatory signals emitted by an obstructed vessel, they release their enzymatic payload directly into the plaque barrier, safely dissolving the mechanical blockage and restoring blood flow without requiring a single invasive incision or stent deployment. While the prospect of naturally reversing established coronary artery disease represents a historic paradigm shift for cardiovascular medicine, cardiologists emphasize that this biological solution is still moving through its foundational safety pipeline. Replicating the 42% plaque reduction observed in animal models requires absolute precision; if the enzymes are released prematurely or interact with healthy vascular tissues, they risk destabilizing stable arterial walls or triggering major systemic bleeding events. Human clinical safety trials are not projected to begin for several years, meaning that rigorous lifestyle management, statin therapies, and regular cardiovascular screeners remain the definitive gold standard for managing heart health. Reference Rossi, M., Bianchi, L., & Ferrero, G. (2026). Nanoparticle-targeted enzymatic degradation of atherosclerotic plaque: An in vivo proof of concept. European Heart Journal, 47(18), 1422-1435.

🧬 𝗧𝗵𝗲 𝗴𝗿𝗲𝗮𝘁𝗲𝘀𝘁 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲 𝘄𝗶𝘁𝗵 𝗻𝗲𝘂𝗿𝗮𝗹 𝗶𝗺𝗽𝗹𝗮𝗻𝘁𝘀 𝗶𝘀 𝗻𝗼𝘁 𝘁𝗼 𝗮𝘁𝘁𝗮𝗶𝗻 𝗯𝗲𝘁𝘁𝗲𝗿 𝗰𝗼𝗻𝗱𝘂𝗰𝘁𝗶𝘃𝗶𝘁𝘆 - 𝗶𝘁 𝗶𝘀 𝗹𝗲𝗮𝗿𝗻𝗶𝗻𝗴 𝘁𝗼 𝗲𝘅𝗶𝘀𝘁 𝗶𝗻 𝗵𝗮𝗿𝗺𝗼𝗻𝘆 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗯𝗿𝗮𝗶𝗻. 🧠 💡 One of the biggest challenges in brain-machine interfaces has never been decoding neural signals, but creating electrodes that the brain can accept without triggering chronic inflammation, gliosis, and signal degradation. 🛜 🔬 A new generation of advanced biomaterials including 𝗣𝗘𝗗𝗢𝗧:𝗣𝗦𝗦, 𝗚𝗿𝗮𝗽𝗵𝗲𝗻𝗲, 𝗠𝗫𝗲𝗻𝗲𝘀, 𝗮𝗻𝗱 𝗖𝗼𝗻𝗱𝘂𝗰𝘁𝗶𝘃𝗲 𝗛𝘆𝗱𝗿𝗼𝗴𝗲𝗹𝘀, is transforming neural engineering by replacing rigid electrodes with soft, flexible interfaces that closely match the mechanical properties of brain tissue. This paradigm shift promises more stable neural recordings, longer-lasting implants, and safer brain-machine interfaces. 🧠 🧬 By bridging materials science, neuroscience, and biomedical engineering, these next-generation neural interfaces are redefining how the brain communicates with technology. 💬 ✍️ Featured Author: Aditi M Warrier, BSc (Hons) Molecular Medicine, Amrita School of Nanosciences and Molecular Medicine (ASNSMM), Kochi, India. 👩🔬 ➡️ NextGen Biology International Newsletter proudly presents its 36th Edition and congratulates Aditi M Warrier for contributing this insightful article in support of our mission to advance impactful science communication in the life sciences. 🧬 🤝 This work was carried out under the supervision of NextGen Biology International Newsletter, in collaboration with the Center for Health Education Training & Neuroscience Awareness (CHETNA) and BrainProt, IIT Bombay, as a collective effort to promote science communication. 💭 #Neuroscience #NeuralEngineering #NeuralInterfaces #NeuralElectrodes #BrainImplants #Neuroprosthetics #BrainResearch #Biomaterials #Biotechnology #BiomedicalEngineering #MaterialsScience #ConductivePolymers #Graphene #MXenes #Hydrogels #ScienceCommunication #NextGenBiology #Newsletter

Israeli researchers have pioneered nanotechnology-based eye drops aimed at correcting refractive errors by reshaping the cornea, potentially eliminating the need for glasses, contacts, or invasive surgery. Unlike conventional options such as corrective lenses or laser procedures, these "nanodrops" involve a multi-step process: a smartphone app measures eye refraction, a low-energy laser etches a customized optical pattern onto the corneal surface, and the nanoparticle solution then activates this pattern to adjust light refraction. Developed by a team from Shaare Zedek Medical Center and Bar-llan University's Institute of Nanotechnology and Advanced Materials, the drops use synthetic protein nanoparticles. Preclinical tests on pigs demonstrated improvements in myopia and hyperopia, with the non-invasive approach offering a convenient, at-home-compatible alternative. This breakthrough could especially aid those with common refractive issues, age-related presbyopia, or conditions previously requiring surgery, minimizing risks, costs, and downtime. While human clinical trials were anticipated following promising animal results around 2018, researchers note the need for additional studies to verify long-term safety and effectiveness. By harnessing nanotechnology for precise corneal modulation, these drops represent a promising step toward simpler more accessible vision corrections in ophthalmology.

🧬 𝐑𝐍𝐀 might be the future of medicine, but it has a problem: 𝐝𝐞𝐥𝐢𝐯𝐞𝐫𝐲! Lipid nanoparticles make RNA drugs work, but they (mostly) go straight to the liver. Not great, if you want to treat anything else! So, what if we had a better vehicle? This paper introduces 𝐚𝐍𝐏𝐬: apolipoprotein-based nanoparticles, that deliver RNA drugs directly to immune cells. They are inspired by natural cholesterol particles, and are: 🎯 Great at targeting bone marrow and spleen 🧩 Versatile, delivering mRNA, siRNA and antisense oligos 💥 Effective, outperforming LNPs on most tasks! Here’s what the team did: 1. Built aNPs using apoA1, a natural cholesterol transporter 2. Optimized the formula using a 72-particle library 3. Screened for RNA encapsulation, delivery, and silencing 4. Validated top hits in mice, with real therapeutic targets The results? ✅ aNP18 delivered siRNA to the bone marrow, not liver ✅ Strong knockdown of target genes (like Lamp1) ✅ Reduced immunosuppressive tumor macrophages by silencing CCR2 ✅ No side effects, and more effective than LNPs! This opens new possibilities for: 💥 Cancer immunotherapy (targeting tumor-suppressive cells) 🛡️ Autoimmune and inflammatory diseases 🧬 Regenerative medicine via RNA reprogramming It’s an important step for RNA delivery, and a reminder to look to nature for solutions! PS: Get the full breakdown here! https://lnkd.in/et9F7MKy #RNAtherapeutics #nanomedicine #drugdelivery #biotech